Payment overview · 2025
General Payments
$1,769.69
94 reported records · 30 companies
Healthcare provider profile · identity verified
Carmel Hensley, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LONDON, KY · NPI 1174918544
Verified facts
What the public records show
CMS Open Payments records show Carmel Hensley, APRN received $1,769.69 in general payments during 2025 across 94 reported records.
ABBVIE INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $392.15 | 22.2% | 25 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $250.76 | 14.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.77 | 8.2% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $117.28 | 6.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $101.79 | 5.8% | 5 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $77.40 | 4.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.77 | 3.8% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $63.10 | 3.6% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.77 | 2.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $49.00 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.30 | 2.6% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $35.57 | 2.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $34.62 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.71 | 1.9% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $33.39 | 1.9% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $22.13 | 1.2% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$21.93 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.90 | 1.2% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $21.82 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.75 | 1.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.69 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.67 | 1.2% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.70 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.9% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.93 | 0.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.16 | 0.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $14.57 | 0.8% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.24 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,685.70 | 93 |
| Education | $83.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $250.76 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.42 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.78 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.03 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.03 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.28 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $101.79 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $100.70 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $93.35 | 7 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $77.40 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.77 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $50.77 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $49.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.30 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.30 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Iodosorb Ointment 40g USA Normalized: iodosorb ointment 40g usa |
Device | Smith+Nephew, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| REGRANEX Normalized: regranex |
Drug | Smith+Nephew, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $11.99 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $9.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 238 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 208 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 54 |
| Lisinopril | Lisinopril | 182 | 47 |
| Montelukast Sodium | Montelukast Sodium | 171 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 38 |
| Omeprazole | Omeprazole | 131 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 41 |
| Losartan Potassium | Losartan Potassium | 118 | 34 |
| Metformin Hcl | Metformin Hcl | 108 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 29 |
| Trazodone Hcl | Trazodone Hcl | 103 | 28 |
| Tramadol Hcl | Tramadol Hcl | 101 | 22 |
| Clonazepam | Clonazepam | 87 | 23 |
| Buspirone Hcl | Buspirone Hcl | 83 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 21 |
| Famotidine | Famotidine | 80 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 24 |
| Ondansetron Odt | Ondansetron | 67 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 18 |
| Furosemide | Furosemide | 62 | 18 |
| Simvastatin | Simvastatin | 61 | 19 |
| Azithromycin | Azithromycin | 60 | 54 |
| Eliquis | Apixaban | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 14 |
| Methocarbamol | Methocarbamol | 55 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 16 |
| Prednisone | Prednisone | 54 | 44 |
| Methylprednisolone | Methylprednisolone | 53 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 24 |
| Allopurinol | Allopurinol | 52 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Sertraline Hcl | Sertraline Hcl | 51 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 40 |
| Cefdinir | Cefdinir | 45 | 43 |
| Permethrin | Permethrin | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Ozempic | Semaglutide | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 30 |
| Meloxicam | Meloxicam | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 13 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Nystatin | Nystatin | 31 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Naproxen | Naproxen | 27 | 12 |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Amoxicillin | Amoxicillin | 22 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 14 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Linzess | Linaclotide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 17 |
| Lactulose | Lactulose | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Indomethacin | Indomethacin | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,769.69 · 94 records | ABBVIE INC. | AMYVID, BRIUMVI, COLLAGENASE SANTYL, CREON, DUPIXENT, EPIDIOLEX, FREESTYLE LIBRE 3, Hizentra, IBSRELA, Iodosorb Ointment 40g USA, KISUNLA, LEQVIO, LINZESS, MOUNJARO, Motpoly XR, NURTEC ODT, Ocrevus Zunovo, Ozempic, PANZYGA, PONVORY, QULIPTA, REGRANEX, REXULTI, REZDIFFRA, Rybelsus, Rystiggo, SKYCLARYS, TZIELD, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VOQUEZNA, VRAYLAR, VYEPTI, VYVGART, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, Zilbrysq | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error